Upadacitinib
Drug Class: DMARDs, Janus Kinase (JAK) inhibitors
Brand Names: Rinvoq
Dosages
15 mg tablet (extended release) once a day
Potential Side Effects
The most common side effects are upper respiratory tract infections, nausea and cough.
Based on a safety trial of the JAK inhibitor tofacitinib (Xeljanz), the FDA has determined upadacitinib and other JAK inhibitors have an increased risk of serious cardiovascular-related events, including heart attack and stroke; cancer, including lymphoma and lung cancer; thrombosis and death.
Special Instructions
Swallow whole. Do not cut, chew, crush, divide or dissolve.
Blood test are required before and during treatment.
Patients should be tested and treated for tuberculosis (TB) before and during use of this drug.
Be Aware
Increased risk of serious viral, invasive fungal and bacterial infections (such as tuberculosis), malignancies (including lymphoma), thrombosis (including deep vein thrombosis and pulmonary embolism) and herpes zoster (shingles).
Do not use if pregnant, planning to become pregnant or breastfeeding.
Do not get live, attenuated vaccines while on this medication.
LAST UPDATED: 09/18/2021
